Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2024 10:30 ET | Source: HiberCell, Inc.

HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce...
May 28, 2024 08:00 ET | Source: HiberCell, Inc.

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine
April 05, 2024 10:00 ET | Source: HiberCell, Inc.

HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366

HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
June 29, 2021 08:00 ET | Source: HiberCell

HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer

NEW YORK, June 29, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of Mark J....
June 10, 2021 08:00 ET | Source: HiberCell

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today...
May 19, 2021 08:00 ET | Source: HiberCell

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital

Proceeds to advance pipeline of clinical product candidates focused on preventing cancer relapse and metastasis NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company...